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Abstract
Introduction: Portal pedicle clamping (PPC) may impact micro-metastases’ growth. This study exam-
ined the association between PPC and survival after a hepatectomy for colorectal liver metastases
(CRLM).
Methods: A matched cohort study was conducted on hepatectomies for CRLM at a single institution
(2003–2012). Cohorts were selected based on PPC use, with 1:1 matching for age, time period and
the Clinical Risk Score. Outcomes were overall and recurrence-free survival (OS and RFS). Cox regres-
sion was performed to assess the association between PPC and survival.
Results: Of 481 hepatectomies, 26.9% used PPC. One hundred and ten pairs of patients were
matched in the cohorts. There was no significant difference in OS [hazard ratio (HR) 1.18; 95% confi-
dence interval (CI): 0.76–1.83], with a 5-year OS of 57.8% (95%CI: 52.4–63.2%) with PPC versus
62.3% (95%CI: 57.1–67.5%) without. Five-year RFS did not differ (HR 0.98; 95%CI: 0.71–1.35) with
29.7% (95%CI: 24.9–34.5%) with PPC versus 28.0% (95%CI: 23.2–32.8%) without. When adjusting for
extent of resection, transfusion, operative time and surgeon, there was no difference in OS (HR 0.91;
95%CI: 0.52–1.60) or RFS (HR: 0.86; 95%CI: 0.57–1.30).
Conclusions: PPC was not associated with a significant difference in OS or RFS in a hepatectomy
for CRLM. PPC remains a safe technique during hepatectomy.
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Introduction
Hepatectomy has become the standard of care for curative
intent treatment of colorectal liver metastases (CRLM). With
broader patient selection and effective multimodal approaches,
overall survival (OS) ranges from 30% to 60% at 5 years.1
However, recurrence remains common and occurs in up to
60% of patients following initial hepatectomy.2
Due to advances in surgical techniques and peri-operative
care, the morbidity profile of hepatectomy has improved sig-
nificantly, with current peri-operative mortality now nearing
1% in high-volume centres.3,4 However, blood loss and need
for a transfusion remain a significant concern that can impact
both immediate and long-term outcomes.5–7 Numerous
intra-operative strategies have been developed to limit blood
loss.8–10 Of these, portal pedicle clamping (PPC), first
described by Hogarth Pringle for liver trauma,11 is one of the
only strategies proven effective to reduce intra-operative blood
loss in randomized controlled trials.12,13
Despite evidence of the efficacy and safety of PPC with
regards to post-operative morbidity and liver failure, the
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uptake of PPC is highly variable. While 30% of Canadian hep-
ato-pancreatico-biliary surgeons use PPC, 40% do so in the
United Kingdom, 50% in Japan and 70% in Continental
Europe.14–17 Concerns remain regarding the long-term onco-
logical effects of PPC due to ischemia–reperfusion injury to
the liver remnant.18,19 Current evidence defining the precise
effect of PPC on oncological outcomes in a CRLM resection is
restricted to studies with small sample sizes from individual
hospitals and cohorts spanning the introduction of modern
patient selection and multi-modal therapy.20–23
The purpose of this study was to ascertain the effect of PPC
on long-term oncological outcomes in a contemporary cohort
of patients undergoing hepatectomy for CRLM.
Patients and methods
A retrospective matched cohort study of a prospectively main-
tained database was conducted. This study was approved by
the Sunnybrook Health Sciences Centre Research Ethics Board.
Patient selection
Patients were identified from a prospectively maintained insti-
tutional database at a tertiary care hepato-pancreatico-biliary
surgery academic centre (Sunnybrook Health Sciences Centre –
Odette Cancer Centre). Adult patients (≥18 years of age)
undergoing an elective liver resection for CRLM from 2003 to
2012 were included.
Patients who underwent PPC were identified and then
matched 1:1 with patients who did not undergo PPC. Match-
ing criteria were age (≤40 years old, 5-year increments, and
≥70 years old), time period of operation (2003–2007, 2008–
2012) and clinical risk score (one-point increments from 0 to
5). The clinical risk score was computed with one point
assigned for each of: node-positive primary malignancy, dis-
ease-free interval < 12 months, more than one hepatic metas-
tasis, largest hepatic metastasis measuring more than 5 cm and
pre-hepatectomy carcinoembryonic antigen >200 ng/ml.24 The
time period cut-off of 2008 was selected to correspond with
the routine introduction of peri-operative systemic treatment
of CRLM at our institution.25 Patients were categorized
according to the matching criteria and a random number gen-
erator used to match corresponding pairs within the same cat-
egories. All PPC patients with a matched control available were
included in the analysis to optimize the sample size. Post-hoc
power calculation was conducted.
Outcomes and data collection
The primary outcome was overall survival (OS), defined as
date of hepatectomy to date of death. The secondary outcome
was recurrence-free survival (RFS), defined as date of hepatec-
tomy to date of recurrence.
The database was queried for data on baseline demo-
graphics, pre-operative systemic treatment, pre-operative
biochemical parameters, intra-operative factors and post-
operative clinical course, including recurrence. Major liver
resection was defined as a resection of 3 or more liver
segments. Major morbidity included grade 3 to 5 Clavien–
Dindo complications.26 Recurrence was defined as intra- or
extra-hepatic biopsy-proven recurrent adenocarcinoma or
lesion deemed suspicious on cross-sectional imaging. Death
data were obtained from the Ontario Cancer Registry
(OCR), a provincial administrative database of Ontario resi-
dents diagnosed with cancer since 1964, receiving hospital
discharge records, pathology reports, death certificates and
reports from regional cancer centres in the province of
Ontario.27
Technical considerations
Liver resections were performed aiming for low central venous
pressure. Intermittent PPC was used at the discretion of the
operating surgeon (no longer than 15 min clamped with
5–10 min unclamped). Hepatic pre-conditioning is not rou-
tinely used. After hepatectomy for CRLM, patients are initially
followed every 3–6 months clinically and radiologically with
cross-sectional imaging of the chest, abdomen and pelvis, for
5 years.
Statistical analysis
Descriptive analysis was performed to compare the characteris-
tics of patients who underwent PPC with those who did not.
Categorical variables were reported as absolute number (n)
with proportion (%), and continuous variables as the median
with interquartile range (IQR). Groups were compared using
Pearson’s chi-square test, Fisher’s exact test and ANOVA, as
appropriate.
Survival analysis was performed using the Kaplan–Meier
method.28 Dates of death from the OCR as of August 8th,
2014 were used, providing a minimum of 24 months of fol-
low-up data for all patients in the cohort. The end of follow-
up for OS analysis was considered as date of death or August
8th, 2014. For RFS, date of first recurrence was used, with
end of the last follow-up defined as date of recurrence, date of
death or date of the last clinical encounter. A sensitivity analy-
sis was conducted for OS and RFS in patients alive 90 days
after a hepatectomy. Differences in OS and RFS were calculated
using the log-rank test.28 The association between PPC and
survival was assessed with Cox regression analysis. Multi-vari-
able Cox regression was used to adjust for relevant clinico-
therapeutic variables identified a priori: operative time (contin-
uous, in hours), receipt of a red blood cell transfusion (cate-
gorical), major liver resection defined as ≥3 segments
(categorical) and surgeon (categorical). Results of Cox regres-
sion were reported as hazard ratios (HR) with 95% confidence
interval (95% CI). Statistical significance was set at P < 0.05.
All analyses were conducted with SPSS 22.0 (IBM Corp.,
Amon, NY, USA).
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Results
Among 851 hepatectomies performed during the study period,
483 were treated for CRLM. Two of those were excluded due
to missing data on PPC use, leaving 481 patients undergoing a
liver resection for CRLM. Of those, 129 (26.9%) underwent
PPC. Four different surgeons performed the hepatectomies
during the study period. Characteristics of the entire cohort,
based on the use of PPC, are detailed in Table 1. The propor-
tion of cases for which they used PPC varied (P < 0.0001),
with 37.6% (50/133), 17.8% (40/224), 31.2% (29/93) and
31.3% (10/31). The median cumulative PPC time was 20 min
(IQR: 15–30 min).
One hundred and ten patients undergoing PPC were
matched to patients operated on without PPC, for a total of
220 patients included in the matched cohort comparative
Table 1 Characteristics of patients undergoing a hepatectomy for colorectal liver metastases, based on portal pedicle clamping (PPC)
status, in the entire cohort
PPC
(n = 129)
No PPC
(n = 352)
P-value
Time period 2008–2012 a 78 (60.5) 251 (71.3) 0.023
Age (years old)a 63 (55–70) 64 (54.2–72.7) 0.635
Male Gender 78 (60.5) 219 (62.2) <0.0001
Pre-operative haemoglobin (g/l) 133.5 (120.2–145) 135 (123–145) 0.128
Pre-operative bilirubin (lmol/l) 7 (5–10) 8 (6–11) 0.755
Pre-operative INR 0.98 (0.94–1.03) 0.98 (0.94–1.03) 0.664
Pre-operative albumin (g/l) 42 (40–45) 42 (39.5–44) 0.881
Pre-operative creatinine (lmol/l) 76 (63.7–85.2) 74 (61.2–87) 0.802
Pre-operative platelet count (109/l) 212.5 (179–252.7) 219 (183–268) 0.151
Clinical risk score a
0 8 (6.2) 44 (12.5) 0.06
1 41 (31.8) 77 (21.9)
2 38 (29.5) 122 (34.7)
3 35 (27.1) 91 (25.9)
4 7 (5.4) 15 (4.3)
5 0 (0) 3 (0.9)
Pre-operative chemotherapy 111 (86.0) 298 (84.7) <0.0001
Major liver resectionb 98 (76.6) 256 (72.7) 0.235
Estimated blood loss (l) 1 (0.5–1.7) 1 (0.5–1.5) 0.182
Operative time (hours) 5.2 (4.1–6.2) 4.4 (3.4–5.7) <0.0001
Intra-operative complication 6 (4.7) 22 (6.3) <0.0001
Perioperative RBC transfusion 34 (26.3) 98 (27.8) 0.828
Major morbidity 18 (13.9) 60 (17.0) 0.380
90-day mortality 10 (7.7) 13 (3.7) <0.0001
Length of stay (days) 7 (6–9) 7 (6–10) 0.128
30-day re-admission 2 (1.6) 16 (4.5) <0.0001
Resection margin status
R0 116 (89.9) 318 (90.3) 0.358
R1 6 (4.7) 15 (4.3)
R2 1 (0.8) 12 (0.6)
Unknownc 6 (4.7) 17 (4.8)
Values are n (%) or median (inter-quartile range).
a
Factors used for matching.
b
Major liver resection: ≥ 3 liver segments resected.
cMargin status could not be identified in the pathology report.
INR, International Normalized Ratio; RBC, red blood cell.
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analysis (Fig. 1). Characteristics of this matched cohort are
presented in Table 2. No difference was observed in therapeu-
tic parameters, including the use of pre-operative chemother-
apy, the performance of a major liver resection, estimated
blood loss, operative time and resection margins. The post-
operative course did not differ significantly based on the use of
PPC, including post-operative morbidity, mortality, length of
stay and the need for a red blood cell transfusion.
With a sample size of 220 patients with a 1:1 distribution
and 66 events, this analysis had 80% power to detect an HR of
1.18 (alpha = 0.05). Overall survival analysis is presented in
Fig. 2. After a median follow-up of 33 (IQR: 20.1–54.8)
months from the date of death, OS did not differ based on the
use of PPC (HR 1.18; 95%CI: 0.76–1.83). Actuarial 3-year and
5-year OS in the PPC and no PPC groups were, respectively,
65.8% (95% CI: 61.0–70.6%) versus 73.6% (95% CI:
69.3–77.9%), and 57.8% (95% CI: 52.4–63.2%) versus 62.3%
(95% CI: 57.1–67.5%). After adjustment for operative time,
red blood cell transfusion, major liver resection and surgeon,
the HR associated with PPC remained non-significant at 0.91
Table 2 Characteristics of patients undergoing hepatectomy for colorectal liver metastases, based on PPC status, in the matched cohort
PPC
(n = 110)
No PPC
(n = 110)
P-value
Time period 2008–2012 a 72 (65.5) 72 (65.5) 1.00
Age (years old)a 63.0 (56.0–72.0) 63.0 (56.0–71.2) 0.921
Male Gender 67.0 (60.9) 75 (68.2) 0.286
Pre-operative haemoglobin (g/l) 134.0 (122.0–145.5) 135.0 (123.0–143.0) 0.281
Pre-operative bilirubin (lmol/l) 7.0 (5.0–9.0) 8.0 (6.0–11.7) 0.241
Pre-operative INR 0.98 (0.93–1.02) 0.98 (0.94–1.03) 0.721
Pre-operative albumin (g/l) 42.0 (40.0–44.7) 42.0 (39.0–45.0) 0.942
Pre-operative creatinine (lmol/l) 76.0 (63.0–84.7) 75.0 (62.0–88.0) 0.445
Pre-operative platelet count (109/l) 208.0 (174.5–250.0) 217.0 (188.0–271.5) 0.035
Clinical risk scorea
0 8 (7.3) 8 (7.3) 1.00
1 32 (29.1) 32 (29.1)
2 37 (33.6) 37 (33.6)
3 29 (26.4) 29 (26.4)
4 4 (2.6) 4 (2.6)
5 0 (0) 0 (0)
Pre-operative chemotherapy 94 (85.5) 87 (79.1) 0.217
Major liver resectionb 69 (63.3) 67 (60.9) 0.715
Estimated blood loss (l) 1.0 (0.5–1.8) 1.0 (0.5–1.5) 0.232
Operative time (hours) 5.1 (4.0–6.1) 4.5 (3.4–5.9) 0.057
Intra-operative complication 5 (4.5) 9 (8.2) 0.322
Peri-operative RBC transfusion 31 (28.2) 26 (23.9) 0.465
Major morbidity 16 (14.5) 20 (18.2) 0.429
90-day mortality 8 (7.3) 7 (6.4) 0.404
Length of stay (days) 7.0 (6.0–9.0) 8.0 (6.0–11.0) 0.100
30-day re-admission 1 (0.9) 5 (4.5) 0.098
Resection margin status
R0 98 (89.1) 102 (92.7) 0.366
R1 6 (5.5) 1 (1.8)
R2 1 (0.9) 0 (0)
Unknownc 5 (4.5) 6 (5.5)
Values are n (%) or median (inter-quartile range).
a
Factors used for matching.
b
Major liver resection: ≥3 liver segments resected.
cMargin status could not be identified in the pathology report.
RBC, red blood cells.
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(95% CI: 0.52–1.6). Excluding patients who died in the first
90 days did not alter the results, with an unadjusted HR of
1.08 (95% CI: 0.63–1.84) and an adjusted HR of 0.66 (95% CI:
0.34–1.31).
For assessment of recurrence, the median follow-up was 23.1
(IQR: 7.7–43.3) months. The median time to recurrence did
not differ: 9.9 (5.7–18.7) months with PPC and 7.9 (3.9–5.7)
months without PPC (P = 0.175). The results of the RFS
analyses are detailed in Fig. 3. No significant difference was
observed in RFS (HR: 0.98; 95% CI: 0.71–1.35). Actuarial RFS
was 35.6% (95% CI: 30.9–40.3%) with PPC versus 38.7%
(95% CI: 33.9–43.5%) without PPC at 3 years, and 28.0%
(95% CI: 23.2–32.8%) with PPC versus 29.7% (95% CI: 24.9–
34.5%) without PPC at 5 years. Adjustment for operative time,
red blood cell transfusions, a major liver resection and surgeon
revealed an HR of 0.86 (95% CI: 0.57–1.30). Results did not
change when restricting the analysis to 90-day survivors with
an unadjusted HR of 0.96 (95% CI: 0.68–1.37) and an adjusted
HR of 0.82 (95% CI: 0.52–1.28).
Discussion
This study compared the long-term outcomes of PPC for a
CRLM resection in a cohort matched on age, clinical risk score
and time period. In this purposefully balanced cohort for
known baseline prognostic factors, neither OS nor RFS differed
based on the use of PPC.
PPC has been studied extensively and shown to be safe with
respect to morbidity and mortality. In addition, the use of
PPC is associated with decreased blood loss and the need for
blood transfusions.12,13,29 Despite these benefits, adoption of
PPC varies widely around the world, perhaps because of
concerns regarding its oncologic impact in overall and recur-
rence-free survival.14–17 The present study was designed with a
view to address this issue.
In the peri-operative period, there was no difference between
the PPC and a non-PPC group with respect to peri-operative
morbidity and mortality, in concordance with other series.12,13,29
Although PPC has been shown to reduce the amount of blood
loss and need for blood transfusions, there was no difference
between our two cohorts. However, there is substantial selection
bias as PPC was used at the discretion of the surgeon in this
non-randomized series. In addition, patients were matched on
prognostic factors pertaining to long-term outcomes and not to
the risk of transfusion, such that effect of PPC on the need for a
transfusion cannot be accurately assessed in this study.
The original impetus for concern regarding ischemia/perfu-
sion created with PPC in inducing rapid growth of liver
metastases arose from observations in animal studies.30–32 For
instance, one murine model of liver metastases reported a five-
to six-fold increase in hepatic metastasis growth in liver lobes
subjected to PPC.32 Several hypotheses have been suggested to
understand the complex local hepatic response to the ische-
mia/reperfusion process and explain these observations, both
acute (early liver tissue damage) and chronic effects (tissue
necrosis).32 Acute hepatocellular injury from inflammatory
cytokines, neutrophil infiltration, hepatocytes edema, an imbal-
ance in pro-constriction and pro-dilation vasoactive substances
and the coagulation system have all been incriminated.33–37 By
creating a fertile ground for tumour growth, such phenomena
could theoretically translate into higher recurrence rates in
humans undergoing a hepatectomy for CRLM. The results pre-
sented herein do not support this hypothesis.
Previous works have assessed the impact of PPC on oncolog-
ic survival outcomes, but were hampered by small sample sizes,
imbalance in the use of PPC and/or time periods bridging the
introduction of modern selection criteria and peri-operative
Figure 1 Flow diagram of patient selection
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Figure 2 Overall survival after a hepatectomy for colorectal liver
metastases, based on portal pedicle clamping (PPC) status, for
the entire cohort (a) and for 90-day survivors (b)
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systemic therapy for CRLM resection.18–23,38 A case-matched
analysis conducted on 60 pairs of patients described a trend in
improved 5-year OS and significantly improved 5-year RFS
with PPC, but was limited by the exclusion of patients with
higher-risk disease.20,24 Other results are consistent with the
lack of a difference in OS and RFS observed in the present
study.18,22,23 Most of those studies spanned across long time
periods, ranging from 1991 to 2008, during which patient
selection, surgical technique and peri-operative medical thera-
pies have significantly changed with an impact on outcomes,1,25
thus limiting their generalizability to contemporary manage-
ment. While some analyses were based on large cohorts of up
to 900 hepatectomies, they were biased by the high frequency
of PPC utilization ranging from 65% to 88% of cases and a
lack of matching techniques to account for the inherent selec-
tion bias.21,22 Finally, one study focused on the long-term
follow-up of patients entered in a randomized, controlled
trial aimed at assessing the impact of PPC on short-term post-
hepatectomy morbidity, from 2002 to 2004.18 It did not
observe a difference in OS or RFS, but it included only 80
patients and was not powered to detect survival differences.
The present study is the largest matched cohort analysis of
oncological outcomes for PPC during hepatectomy for
CRLM. Confounders introduced by patient selection were
taken into consideration by matching on number and size of
liver lesions included in the CRS and multivariable regression
accounting for surrogates of technical challenge (operative
time, red blood cell transfusion and major resection).24 Such
detailed analysis strengthens the findings. This study focused
on OS and all site RFS. The data available in the institutional
database did not allow for reliable assessment of the patterns
of recurrence with specific assessment of liver RFS, which
could theoretically be more affected by PPC. However,
beyond the pattern of recurrence, OS was not affected by
PPC, and remains one of the most clinically relevant apprai-
sal tools of a cancer patient’s ultimate outcome. Finally, the
exact impact of prolonged cumulative PPC time could not be
assessed due to small numbers within the PPC group and the
overall short median cumulative PPC time (20 min). The ori-
ginal PPC murine models focused on longer continuous PPC
time than that used with the intermittent clamping tech-
nique.32 Thus far, only one group has suggested that the
impact of PPC on OS and RFS may be more apparent only
in prolonged PPC, based on a sub-group of 50 patients and
without accounting for selection bias.19 This observation has
been refuted by others.18,21–23
This study is subject to the inherent weaknesses of its ret-
rospective design, including selection bias, information bias
and unknown confounders. First, the decision to proceed
with PPC was dependent on the surgeon. Second, PPC might
have been used for more difficult cases due to more complex
disease, higher blood loss or more damaged liver parenchyma.
As previously mentioned, prognostic factors were controlled
for by matching cohorts, and known confounders pertaining
to a technical challenge and surgical risk were adjusted for by
multivariable regression analysis. Additionally, the current
findings are limited to the intermittent PPC technique and
cannot be extrapolated to the continuous one. Finally, details
of recurrence patterns were not reliably captured as patients
often had their care returned to the referring centre.
Conclusion
In this study, PPC was not associated with OS and all-site RFS
in patients undergoing a hepatectomy for CRLM in patients
matched for age, time period of operation and clinical risk
score. PPC does not negatively affect oncological outcomes
and remains a safe strategy in hepatectomy for CRLM.
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